The MiniMed continuous glucose monitoring system.
The MiniMed continuous glucose monitoring system.
复制标题
DOI：
10.1089/15209150050214078
复制
发表时间：
2000-01-01
影响因子：
5.4
通讯作者：
Mastrototaro, J J
中科院分区：
文献类型：
--
作者：
Mastrototaro, J J
糖尿病是发病率、死亡率和经济支出的主要来源。在美国，所有1型糖尿病患者和大约3-4百万2型糖尿病患者必须服用胰岛素来控制血糖水平。这些患者中的大多数每天自我监测血糖一次或多次，使用便携式血糖仪设备进行手指抽血和分析。在美国，大约有20万1型糖尿病患者进行强化胰岛素治疗，每天需要四次或更多的血糖测量，加上每天多次注射胰岛素或胰岛素泵。糖尿病控制和并发症试验（DCCT）清楚地证明了频繁的自我血糖监测（SMBG）对实现严格的血糖控制的重要性。1与接受常规治疗的患者相比，接受强化治疗的患者长期并发症发生率降低了39-76%。强化治疗的主要缺点是严重低血糖的发生率增加了三倍，尽管每天进行四次或更多次SMBG检测。因此，如何在不发生低血糖的情况下提高强化控制能力的方法正在探索中。我们迫切需要开发一种真正简单、准确的血糖测量方法，并将其商业化，从而为更准确、更有针对性的疾病自我管理提供基础。一般来说，在一天中频繁地进行SMBG以准确识别每一次血糖偏移是不现实的。MiniMed®已经迈出了第一步
DIABETES is a major source of morbidity, mortality, and economic expense. All patients with type 1 diabetes and an estimated 3–4 million patients in the United States with type 2 diabetes must take insulin to control their glucose levels. The majority of these patients selfmonitor their blood glucose one or more times each day, using fingerstick blood sampling and analysis with a portable glucose meter device. Approximately 200,000 type 1 diabetes patients in the United States practice intensive insulin therapy, requiring four or more blood glucose measurements each day coupled with either multiple daily injections of insulin or an insulin pump.The Diabetes Control and Complications Trial (DCCT) clearly demonstrated the importance of frequent self-monitoring of blood glucose (SMBG) in attaining tight glycemic control. 1 Patients undergoing intensive therapy had a 39–76% reduced occurrence of long-term complications as compared to patients treated with conventional therapy. The primary drawback of intensive therapy was a threefold increase in the occurrence of severe hypoglycemia, despite performing four or more SMBG tests per day. Consequently, methods to improve the ability to achieve intensive control without hypoglycemia are being explored. There is a tremendous need to develop and commercialize a truly simple, accurate method of measuring glucose that can provide a basis for more accurate and directed disease selfmanagement. Generally, it is not practical to perform SMBG frequently enough throughout the day to accurately identify every blood glucose excursion. MiniMed® has taken a first step